Skip to content

Sex on HRT

Estrogen and androgen suppression reorganize the sexual-functioning physiology of trans-feminine bodies on a predictable arc. Libido shifts in pattern, not just magnitude. Erections decay in reliability and firmness. Orgasm reorganizes from a localized spike-and-discharge event toward a more distributed, longer, less ejaculation-bound experience. Ejaculate diminishes or disappears entirely. None of these changes are uniform across people, and none are dysfunctions in the long-term-care sense — they are the expected acute-and-mid-term physiology of HRT.

This page covers what changes, when it changes, and what range of normal looks like during the first 2–3 years on HRT. For the long-arc dysfunction layer (low libido as a chronic complaint, persistent dyspareunia, atrophy management) see Long-Term Care → Sexual Health Long-Term. For drug-class-specific effects see HRT → Anti-androgens and HRT → Estrogens.

Framing the four domains

Feminizing HRT acts on four functional domains — libido, erection, orgasm, ejaculation — on overlapping but distinct timelines. They are not tightly coupled. A patient can lose spontaneous erections within weeks while retaining stimulated erections for years; can lose ejaculate while preserving orgasm; can have intact orgasm with collapsed libido. Treating these as one bundle ("sex got worse / better / different") obscures what is actually happening and blocks targeted assessment.

The dominant driver is androgen withdrawal, not estradiol. Estradiol contributes skin and sensation effects and modulates central desire modestly, but the erection-and-ejaculation timeline is anti-androgen-driven. Patients on GnRH-agonist monotherapy or post-orchiectomy without estradiol experience similar erection trajectories.

The Endocrine Society guideline (Hembree 2017) and WPATH SOC v8 both note sexual function changes as expected effects of feminizing therapy without prescribing a clinical timeline. The longitudinal data — what changes when — comes mostly from the ENIGI cohort (Defreyne 2020), the Ghent group (Wierckx 2014, Kerckhof 2019), and the Holmberg/Arver/Dhejne 2019 review.

Pre-HRT vs post-HRT at a glance

The table below sketches the typical year-1+ baseline against pre-HRT physiology on natal androgens. Individual trajectories vary — the variation section covers why.

Domain Pre-HRT (natal androgens) Post-HRT (year 1+, adequate suppression)
Libido Frequent spontaneous urge, mounting pressure, ejaculation-bound resolution Responsive pattern — desire arises in response to context, stimulation, intimacy
Erection Reliable spontaneous and morning erections; rapid stimulated erection on demand Spontaneous and morning erections rare or absent; stimulated erection variable, slower-built
Orgasm Fast build to brief, intense, localized peak with ejaculation Longer build, less sharply-peaked, more distributed across body and skin
Ejaculation Normal volume, ejaculation-coupled to orgasm Anejaculation or trivial volume; orgasm uncouples from ejaculation
Sensation Sharp focal genital sensation; skin sensitivity at male-typical levels Softer, more diffuse genital sensation; increased skin sensitivity, expanded erogenous mapping
Refractory Defined refractory period after orgasm, strongly reduced desire and capacity Refractory often shortened or absent; subset develop multi-orgasm capacity

The HRT timeline of sexual-function change

The four domains move on overlapping timelines anchored to androgen suppression. The sub-sections below describe the typical trajectory on adequate anti-androgen + estradiol dosing. Partial suppression slows everything; deeper suppression (cyproterone, GnRH agonist) accelerates and deepens the effects.

Weeks 0–4: anti-androgen onset

  • Total testosterone falls from male reference range toward the suppressed target (typically <50 ng/dL by week 4–6 on adequate dosing) on spironolactone, cyproterone, GnRH agonist, or bicalutamide.
  • Spontaneous erection frequency is the first thing most patients notice changing. Nocturnal and morning erections are androgen-dependent and decline in step with serum T.
  • Libido frequency may increase transiently in some patients in the first 2–3 weeks (pre-suppression rebound or anticipation effect); this is not a reliable phenomenon and should not be planned around.
  • Estradiol is often only partially titrated this window; most early sexual changes are anti-androgen effects, not estrogen effects.

Months 1–3: erection decline becomes noticeable

  • Spontaneous erections become rare or absent for most patients by week 8–12.
  • Morning erections are typically lost by month 3 on adequate suppression. Their loss is one of the most reproducible markers of effective androgen blockade.
  • Stimulated erection firmness begins to drop. Patients describe a longer build, less complete rigidity, and faster detumescence after stimulation ends.
  • Ejaculate volume reduces. Some patients report this earlier than erection changes; physiologic basis is androgen-dependent prostate and seminal-vesicle output.
  • Libido frequency starts dropping for most. Intensity per occasion is variable and often preserved early.

Months 3–6: libido pattern shift

  • The character of desire changes more than its presence. Most patients report a shift from spontaneous, intrusive, mounting urgency ("drive") to context-dependent, responsive, slower-building interest. This is the physiologic correlate of removing testosterone's central drive contribution.
  • Frequency of spontaneous sexual thoughts drops; responsive desire — desire that arises in response to stimulation, partner, or context rather than ahead of it — becomes the dominant pattern for most.
  • HSDD-criterion scores rise in cohort data: Defreyne 2020 (ENIGI, n=766) reported ~27–34% of trans-feminine patients meeting Hypoactive Sexual Desire Disorder cutoffs at 3–12 months, against ~15% in cis comparison populations.
  • Ejaculate volume continues falling; some patients reach anejaculation in this window, others retain small volume to year 1.

Months 6–12: orgasm reorganization

  • Orgasm character shifts from the pre-HRT spike-and-discharge pattern toward a longer-build, more distributed, less-localized experience. This is the most consistently reported qualitative change.
  • Orgasm latency increases. Time-to-orgasm with the same stimulation is typically longer than pre-HRT.
  • Some patients report multi-orgasm becoming possible in this window — second and subsequent orgasms within a session, with shorter or absent refractory period. This is not universal and is most often described after month 6.
  • A subset develops anorgasmia or near-anorgasmia in this window. Wierckx 2014 and Kerckhof 2019 reported orgasmic-dysfunction prevalences in the 15–30% range in pre-vaginoplasty cohorts at year 1.
  • Ejaculate is absent or trivially small for most by year 1.

Year 1+: a new baseline

  • For most patients sexual physiology stabilizes at a new operating point between months 12 and 24. Further drift past year 2 is usually small and modulated by anti-androgen choice, dose, partner status, mental health, and age.
  • The new baseline is heterogeneous: some patients report a satisfying and internally coherent sexual life at lower frequency; some report persistent loss they would change if they could; some report no meaningful difference in subjective satisfaction despite measurable changes on instruments.
  • Population-level data: validated instruments (FSFI, SDI) flag dysfunction in 30–40% at year 1+; self-reported satisfaction surveys hover at 75–85%. Population libido loss is real but is often not subjectively a problem.

Timeline applies to adequate suppression

The arc above assumes adequate androgen suppression — total T below ~50 ng/dL on consistent dosing. Under-suppressed patients (retained morning erections at month 3+, retained pre-HRT-pattern libido) follow a slower or partial trajectory. Persistent pre-HRT-pattern function past month 6 on supposedly full suppression is a reason to recheck total T and revisit anti-androgen dose.

Libido changes

Frequency vs intensity

These are separable and need separating in clinical questioning.

  • Frequency — how often desire arises, how often sexual thoughts intrude, how often masturbation occurs. This drops for most patients within 3–6 months of effective suppression.
  • Intensity — strength of desire when it does arise, vividness of arousal, subjective involvement during sex. This is more variable. Some patients report intensity preserved or increased even as frequency collapses.

A patient saying "my libido is gone" usually means frequency. Intensity per occasion is often a separate conversation, and one worth having before concluding that desire itself has disappeared.

Drive vs interest

The clearest framing is the spontaneous-vs-responsive desire model.

  • Pre-HRT desire pattern in most trans-feminine patients on natal androgens resembles the male-typical pattern — frequent spontaneous urge, mounting pressure, ejaculation-bound resolution.
  • Post-HRT desire pattern more often resembles the responsive model — desire arises in response to stimulation, intimacy, fantasy, or context, rather than spontaneously demanding outlet.
  • Many patients describe this as relief; some describe it as loss; some describe it as both. Framing matters for whether the shift is treated as a complaint or as a baseline.

Cycle-like patterns

A meaningful subset develop multi-day cyclical desire patterns on stable HRT — peaks and troughs over a 3–6 week interval, sometimes longer. Mechanism is not established (estradiol is administered continuously, not cyclically, in most regimens). Reports are clinical, not from controlled tracking. Patients who notice this pattern can sometimes work with rather than against it; a brief desire log over 8–12 weeks makes the pattern visible if it exists.

Low libido as complaint vs identity

  • Low libido is a clinical complaint when the patient experiences distress about it, when it interferes with a partnered relationship, or when it is accompanied by other anhedonic or depressive features.
  • Low libido is not a clinical complaint when the patient does not experience distress, finds the new baseline coherent, or identifies as asexual or gray-asexual on reflection. A subset of trans-feminine patients on HRT come to identify as asexual; some pre-HRT asexual identity is made visible by HRT, some is post-HRT self-understanding. See Sexual Orientation, Identity & Libido Shifts.
  • HSDD prevalence in trans-feminine populations on HRT is approximately 22–34% across published cohorts (Wierckx 2014, Defreyne 2020), roughly double cis-female baseline. The diagnosis requires distress; many patients with low desire scores do not meet HSDD criteria.

Erection changes

Firmness and reliability decline

Both firmness (rigidity at peak) and reliability (probability of achieving useful erection on stimulation) drop within 1–6 months of adequate androgen suppression. The two do not necessarily move together — some patients lose reliability first while retaining firmness when erection does occur, others lose firmness first while still erecting on most attempts.

Spontaneous erections diminish

Spontaneous (non-stimulated) daytime erections become rare or absent for most patients by month 3–6. This is one of the most consistent androgen-withdrawal effects.

Morning and nocturnal erections

REM-sleep erections (the physiologic basis of morning erections) are testosterone-dependent. They typically disappear within 8–12 weeks of adequate suppression. Their loss is a useful marker of effective anti-androgen dosing — persistent morning erections at month 3+ on supposedly adequate suppression is a reason to recheck total T.

Stimulated erections — variable retention

This is the most heterogeneous domain.

  • Some patients retain useful stimulated erections indefinitely, including for partnered penetrative sex, on full suppressive HRT.
  • Some lose stimulated erection capacity within 6–12 months and do not recover it without PDE5 inhibitors or pump.
  • Most are somewhere between — stimulated erections are achievable but slower to build, less rigid, less durable, and require more direct stimulation than pre-HRT.

PDE5 inhibitor (sildenafil, tadalafil) efficacy is reduced versus cis-male use because the corporal smooth muscle and vasculature itself atrophies on prolonged androgen suppression — these drugs potentiate an underlying mechanism that is itself reduced.

Anti-androgen vs estrogen contributions

  • The dominant driver of erectile change is androgen withdrawal, not estradiol. Patients on GnRH-agonist monotherapy or post-orchiectomy without estradiol experience similar erection trajectories.
  • Estradiol contributes secondarily through corporal-tissue effects on prolonged exposure (penile-tissue feminization, mild atrophy at year 2+), but the acute timeline is androgen-driven.
  • Cyproterone produces deeper T suppression than spironolactone at typical doses and is associated with more complete erection loss in cohort data. See Anti-androgens for drug-class detail.

Erection function is not sexual function

A large portion of trans-feminine patients on HRT have a satisfying sexual life with diminished or absent erections — through manual, vibratory, or receptive stimulation, partnered or solitary. Conflating "I cannot reliably erect" with "I cannot have sex" is clinically and personally counterproductive. For practical re-mapping after erection change, see Solo Sex and Partnered Sex Pre-Surgery.

Orgasm reorganization

Pre-HRT pattern

The natal-androgen pattern in trans-feminine bodies pre-HRT is typically spike-and-discharge — fast build to a brief, intense, localized peak with ejaculation, followed by a refractory period with strongly reduced desire and capacity for further orgasm. Sensation is concentrated at the penis.

Post-HRT pattern

The post-HRT pattern is most often described as longer build, less sharply-peaked, more distributed across body and skin, and less tied to ejaculation (which is reduced or absent). Sensation is less concentrated at the penis and more diffuse — chest, neck, skin, and other areas often become more involved. Some patients describe it as "fuller-body."

This is not universal — a subset retain a recognizably similar pattern to pre-HRT, particularly on lower anti-androgen doses or with partial suppression.

Orgasm latency

Time-to-orgasm typically increases. Patients who pre-HRT could orgasm in 2–5 minutes of direct stimulation often need 10–20+ minutes post-HRT. This is not premature ejaculation reversing — it is a separate physiologic shift related to reduced central androgen drive and altered penile sensation.

Multi-orgasm

A subset of patients develop multi-orgasm capacity on HRT — two or more orgasms within a session, with reduced or absent refractory period between them. Reports usually emerge after month 6. Mechanism is not established; it parallels (but is not identical to) cis-female multi-orgasmic patterns.

When orgasm becomes harder to reach

Anorgasmia or near-anorgasmia at year 1 is reported in 15–30% of pre-vaginoplasty trans-feminine patients on HRT (Kerckhof 2019, pooled cohorts). Three patterns recur:

  • New-onset, persistent. Was orgasmic pre-HRT, lost capacity within year 1, has not recovered. Multifactorial — central drive reduction, corporal atrophy, dysphoria, SSRI use, partnered context.
  • New-onset, transient. Loss in the 6–18 month window, gradual return with adapted technique and longer build. Common.
  • Pre-existing. Pre-HRT anorgasmia carried forward; HRT did not change it.

When anorgasmia is distressing and persists past year 1, sex-medicine referral is appropriate. See Long-Term Care → Sexual Health Long-Term for the chronic-dysfunction layer.

Ejaculation changes

Volume reduction

Ejaculate volume drops within weeks of effective T suppression — visible within the first 1–3 months for most patients. The driver is reduced androgen-dependent secretion from the prostate and seminal vesicles.

Anejaculation by year 1

By year 1 on adequate suppression most patients are anejaculatory or produce only trivial volume. This is expected and not a sign of dysfunction.

Wet vs dry orgasm

Pre-HRT orgasm is wet (ejaculation-coupled). Post-HRT orgasm is increasingly dry — the orgasmic experience uncouples from ejaculation, and most patients at year 1+ orgasm without measurable ejaculate. The orgasm itself can be fully present without the discharge component.

Fertility implications

Sperm production drops with androgen suppression and is largely abolished at year 1+ on full HRT. Recovery on stopping HRT is variable and not guaranteed; some patients regain fertile sperm counts after months off, some do not. Sperm cryopreservation before HRT is the only reliable preservation strategy for patients who want a biological-fertility option. See Long-Term Care → Fertility.

Sensation changes

Genital sensitivity

Penile and scrotal sensitivity changes are variable and not as well characterized as the erection-and-orgasm changes. Most patients report some shift — often a softer, more diffuse sensation rather than the sharp focal sensation of pre-HRT. A minority report reduced sensitivity to the point of hypoesthesia; a minority report increased or qualitatively different sensation.

Skin sensitivity (estrogen-mediated)

Increased skin sensitivity is one of the more consistently reported estrogen-mediated changes. Touch, temperature, and texture become more salient; light skin contact can produce more arousal than pre-HRT. Mechanism is partially peripheral (skin and subcutaneous tissue changes under estrogen) and partially central (altered processing of tactile input).

Erogenous-zone shifts

Many patients report new or expanded erogenous zones, most often:

  • Chest and nipples (often dramatically increased, sometimes painful early in breast development before settling)
  • Neck and ears
  • Inner thighs
  • Lower back
  • Whole-skin response to light touch

Areas that were highly erogenous pre-HRT may become less so, or stay similar. Re-mapping is a normal early-HRT exercise — see Solo Sex.

"I feel things differently"

A common patient report is qualitative — "the same touch produces a different feeling." This is consistent with central processing changes under estrogen on top of peripheral receptor changes; it does not have a single anatomical localization.

Variation and ranges

Why responses vary widely

  • Dose and suppression depth. Partial androgen suppression produces partial physiologic change. Cohorts differ in T targets and anti-androgen use; trajectories follow.
  • Anti-androgen choice. Cyproterone produces deeper suppression and stronger CNS effects than spironolactone or bicalutamide; libido and erection trajectories differ accordingly.
  • Age at start. Younger patients tend to retain more erectile function and recover orgasmic capacity more readily than older patients on comparable suppression.
  • Baseline sexual function. Patients with strong pre-HRT sexual function have more to retain; patients with pre-HRT dysfunction often see it carry forward or worsen.
  • Comorbidities and medications. SSRIs, antipsychotics, opioids, gabapentinoids, hypertension, diabetes, and depression all independently reduce sexual function and stack with HRT effects.
  • Surgical status. Orchiectomy permanently removes the testicular androgen source; vaginoplasty replaces the natal-genital substrate entirely. Both restructure what "sexual function" means.

Dose-response considerations

Within physiologic estradiol ranges (roughly 100–200 pg/mL) there is no reliable dose-response for sexual function — supraphysiologic E2 does not recover libido and adds clot and breast risk. Anti-androgen depth does matter: under-suppressed T preserves more erection but interferes with feminization; over-suppressed T (CPA, GnRH) collapses libido more deeply.

Anti-androgen choice impact

Drug Libido / desire Erection
Spironolactone Moderate reduction Moderate reduction
Cyproterone Strongest reduction (CNS + deep T suppression) Most complete erection loss
Bicalutamide Some patients report better-preserved libido Erection often better preserved
GnRH agonist Strong reduction (castrate-level T) Strong reduction

Bicalutamide data is small case series; CPA data is the most consistent on strongest suppression. For drug-class detail, see Anti-androgens.

When to investigate

Distinguishing expected change from dysfunction

Expected on HRT in the 0–24 month window:

  • Loss of spontaneous and morning erections
  • Reduced ejaculate to anejaculation
  • Reduced libido frequency, shifted desire pattern
  • Longer orgasm latency, distributed orgasm character
  • Variable retention of stimulated erection

Worth investigating:

  • Complete anorgasmia past year 1 with subjective distress
  • Persistent erection of pre-HRT firmness past month 6 on supposedly full suppression (suggests inadequate anti-androgen)
  • Genital pain (not covered on this page — see Long-Term Care → Sexual Health Long-Term)
  • Sudden change in established post-HRT baseline (months of stable function followed by abrupt loss)
  • Libido loss accompanied by other anhedonic or depressive features
  • Sexual side effects of newly-started medications (SSRIs, antipsychotics)

Sudden change in a stable baseline is not expected

The HRT timeline produces gradual, monotonic-ish change over 0–24 months. An abrupt change in established post-HRT function — months of stable function followed by sudden loss — is not the HRT arc and warrants a workup. Common drivers: a new psychotropic, a dose change, a new comorbidity (thyroid, prolactinoma, depression), or a relationship-context shift. Do not assume "more HRT effect" without ruling these out.

When to bring it to your endocrinologist

  • Adequacy-of-suppression questions. Persistent morning erections, retained pre-HRT-pattern function suggesting under-suppression, or the inverse — near-total libido collapse on CPA where switching may help.
  • Anti-androgen choice review. CPA-related libido collapse, considering switching to spironolactone or bicalutamide.
  • Lab review. Total T, free T, estradiol, prolactin (high prolactin can reduce desire independently).
  • Medication interaction review. Any new psychotropic with sexual side effects; any newly started medication coinciding with the change.

When to see a sex-medicine clinician

  • Persistent anorgasmia with distress past year 1
  • Erection change that interferes with a goal the patient holds (e.g. retaining penetrative function pre-vaginoplasty for a partnered context)
  • Pelvic-floor dysfunction features (often missed)
  • Mismatch between physiologic findings and subjective experience
  • Cross-link to Long-Term Care → Sexual Health Long-Term for the chronic-dysfunction layer

Sources

  • Hembree WC et al. (2017) — Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 102(11):3869–3903. doi:10.1210/jc.2017-01658
  • Coleman E et al. (2022) — Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health 23(S1):S1–S259. Sexual-health chapter. doi:10.1080/26895269.2022.2100644
  • Defreyne J et al. (2020) — Sexual desire changes in transgender individuals upon initiation of hormone treatment: results from the longitudinal ENIGI study. J Sex Med 17(4):812–825. doi:10.1016/j.jsxm.2019.12.020
  • Wierckx K et al. (2014) — Sexual desire in trans persons: associations with sex reassignment treatment. J Sex Med 11(1):107–118. doi:10.1111/jsm.12365
  • Holmberg M, Arver S, Dhejne C (2019) — Supporting sexuality and improving sexual function in transgender persons. Nat Rev Urol 16(2):121–139. doi:10.1038/s41585-018-0108-8
  • Kerckhof ME et al. (2019) — Prevalence of sexual dysfunctions in transgender persons: results from the ENIGI follow-up study. J Sex Med 16(12):2018–2029. doi:10.1016/j.jsxm.2019.09.003
  • Klein C, Gorzalka BB (2009) — Sexual functioning in transsexuals following hormone therapy and genital surgery: a review.
  • Costantino A et al. (2013) — A prospective study on sexual function and mood in female-to-male transsexuals during testosterone administration and after sex reassignment surgery. Cited as method/comparator reference.
  • Lawrence AA — multiple — patient-reported outcomes and sexuality after vaginoplasty; qualitative descriptions of orgasm reorganization and desire pattern shifts.